UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of

1934

Date of Report (Date of earliest event reported): August 15, 2007

PFIZER INC.

(Exact

name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of

incorporation)

1-3619

(Commission File Number)

13-5315170

(I.R.S. Employer Identification

No.)

235 East 42nd Street, New York, New

York 10017

(Address of

principal executive offices) (zip code)

(212) 573-2323

(Registrant's telephone

number)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the obligation of the registrant

under any of the following provisions:

[ ] Written communication

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule

14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule

13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other

Events

Exhibit 100 to this Current Report on Form 8-K

contains documents formatted in XBRL (eXtensible Business Reporting Language)

with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the

quarter ended July 1, 2007, filed with the Securities and Exchange

Commission (SEC) on August 6, 2007. The information formatted in XBRL includes

the (i) Condensed Consolidated Statements of Income for the three months and six months ended July

1, 2007, and July 2, 2006, (ii) Condensed Consolidated

Balance Sheets at July 1, 2007 and at December 31, 2006, and (iii)

Condensed Consolidated Statements of Cash Flows for the six months ended July

1, 2007 and July 2, 2006.

Users of this data are advised pursuant to Rule

401 of Regulation S-T that the financial information contained in the

XBRL-Related Documents is unaudited and these are not the official financial

statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these

XBRL formatted documents is solely for the purpose of participation in the SEC's

voluntary XBRL pilot program to test the related format and technology and, as a

result, investors should continue to rely on the official filed version of the

furnished documents and not rely on the information in this Current Report on

Form 8-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of

Regulation S-T, the information in this Current Report on Form 8-K, including

Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18

of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or

otherwise subject to the liability of that section, and shall not be

incorporated by reference into any registration statement or other document

filed under the Securities Act of 1933, as amended, or the Exchange Act, except

as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and

Exhibits.

(d)

Exhibits

The following exhibits are furnished

herewith:

Exhibit

Number

Exhibit

Description

100

The following financial statements from

Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended

July 1, 2007, filed on August 6, 2007, formatted in XBRL

(eXtensible Business Reporting Language): (i) the Condensed Consolidated

Statements of Income for the three months and six ended July 1, 2007, and

July 2, 2006, (ii) the Condensed Consolidated Balance Sheets at

July 1, 2007 and December 31, 2006, and (iii) the Condensed

Consolidated Statements of Cash Flows for the six months ended

July 1, 2007 and July 2,

2006.

SIGNATURE

Under the requirements of the Securities

Exchange Act of 1934, the registrant has caused this report to be signed

on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M.

Foran

Margaret M. Foran

Dated: August 15, 2007

Title: Senior Vice

President-Corporate Governance

Associate General Counsel and Corporate

Secretary

EXHIBIT INDEX

Exhibit No.

Description

EX-100.INS

XBRL Instance Document

EX-100.SCH

XBRL Taxonomy Extension Schema

Document

EX-100.SCH.1

XBRL Schema Supplement Document

EX-100.CAL

XBRL Taxonomy Extension Calculation

Linkbase Document

EX-100.LAB

XBRL Taxonomy Extension Label Linkbase

Document

EX-100.PRE

XBRL Taxonomy Extension Presentation

Linkbase Document